Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 20, 2025
Daily News
August 20, 2025
- Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
August 20, 2025
- FRONTEO, Daiichi Sankyo Expand AI Collaboration into Toxicity Data Analysis
August 20, 2025
- PPIs Prescribed to 6.38 Million in July, Two APIs Control 60%: Intage
August 20, 2025
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Foreign Pharma Sales in Japan Projected to Rise 1.8% in 2025: Fuji Keizai
August 20, 2025
- Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
- Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
August 20, 2025
- Daiichi Sankyo Snares First FDA Breakthrough Tag for ADC I-DXd
August 20, 2025
- Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
- Mounjaro Wins Double Crown in June GP Promotion: Intage
August 20, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…